Pitavastatin and carbohydrate metabolism: What is the evidence?

Expert Review of Clinical Pharmacology

Volumn 9, Issue 7, 2016, Pages 955-960

  Filippatos, T D ^a   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adiponectin; Carbohydrate; Diabetes; Glucose; Mechanisms; Oxidative stress; Pitavastatin; Statin

Indexed keywords

CARBOHYDRATE; PITAVASTATIN; ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; QUINOLINE DERIVATIVE;

CARBOHYDRATE METABOLISM; CLINICAL PHARMACOLOGY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; OXIDATIVE STRESS; RISK;

ADIPONECTIN; ANIMALS; CARBOHYDRATE METABOLISM; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATIVE STRESS; QUINOLINES; RISK;

EID: 84961626019     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1165607     Document Type: Review

References (60)

1. Cholesterol Treatment Trialists C, J.Fulcher, R.O’Connell, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405.
2. T.D.Filippatos, D.P.Mikhailidis Statins and heart failure. Angiology. 2008;59(2 Suppl):58S–61S.
3. T.D.Filippatos, M.S.Elisaf. Effects of ezetimibe/simvastatin combination on metabolic parameters. Int J Cardiol. 2016;202:273–274.
4. A.P.Agouridis, C.V.Rizos, M.S.Elisaf, et al. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud. 2013;10(2–3):171–190.
5. A.P.Agouridis, V.Tsimihodimos, T.D.Filippatos, et al. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids. 2011;46(6):521–528.
6. T.D.Filippatos, M.S.Elisaf. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12(12):1945–1958.
7. T.D.Filippatos, M.S.Elisaf. Statin-ezetimibe combination therapy In diabetic individuals. Angiology. 2015. [Epub ahead of print].
8. R.B.Iwere, J.Hewitt. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(3):363–371.
9. D.N.Kiortsis, T.D.Filippatos, D.P.Mikhailidis, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007;195(1):7–16.
10. T.D.Filippatos, M.S.Elisaf. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf. 2015;14(9):1481–1493.
11. D.Preiss, S.R.Seshasai, P.Welsh, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564.
12. S.Erqou, C.C.Lee, A.I.Adler. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014;57(12):2444–2452.•• A meta-analysis showing that statins may slightly deteriorate glycemic control of diabetic patients.
13. P.Kohli, D.D.Waters, R.Nemr, et al. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. J Am Coll Cardiol. 2015;65(4):402–404.
14. P.M.Ridker, E.Danielson, F.A.Fonseca, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
15. N.Sattar, D.Preiss, H.M.Murray, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742.•• A meta-analysis showing the assosiation of statins with increased risk of incident diabetes.
16. D.I.Swerdlow, D.Preiss, K.B.Kuchenbaecker, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351–361.
17. A.P.Agouridis, M.S.Kostapanos, M.S.Elisaf. Statins and their increased risk of inducing diabetes. Expert Opin Drug Saf. 2015;14(12):1835–1844.
18. A.Bellia, S.Rizza, M.F.Lombardo, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223(1):197–203.
19. M.S.Kostapanos, A.P.Agouridis, M.S.Elisaf. Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia. 2015;58(8):1960–1961.
20. M.S.Kostapanos, C.V.Rizos, M.S.Elisaf. Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. Drug Saf. 2014;37(7):481–500.
21. A.Kei, E.Liberopoulos, M.Elisaf. Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. World J Diabetes. 2013;4(6):365–371.
22. M.S.Kostapanos, G.L.Liamis, H.J.Milionis, et al. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol. 2010;8(5):612–631.
23. D.Nowis, A.Malenda, K.Furs, et al. Statins impair glucose uptake in human cells. BMJ Open Diabetes Res Care. 2014;2(1):e000017.
24. M.Nakata, S.Nagasaka, I.Kusaka, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49(8):1881–1892.
25. M.Schachter. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117–125.
26. W.L.Baker, R.Talati, C.M.White, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87(1):98–107.
27. P.M.Ridker, A.Pradhan, J.G.MacFadyen, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–571.
28. T.Teramoto, H.Shimano, K.Yokote, et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother. 2010;11(5):817–828.
29. M.J.Chapman, A.Orsoni, P.Robillard, et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin. 2014;30(5):775–784.
30. K.Kajinami, N.Takekoshi, Y.Saito. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003;21(3):199–215.
31. R.Y.Mukhtar, J.Reid, J.P.Reckless. Pitavastatin. Int J Clin Pract. 2005;59(2):239–252.
32. A.Corsini, S.Bellosta, R.Baetta, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84(3):413–428.
33. D.Shang, S.Deng, Z.Yao, et al. The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese male subjects. Xenobiotica. 2015;46(1):34–39.
34. S.Morikawa, M.Umetani, S.Nakagawa, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7(3):138–144.
35. S.H.Choi, S.Lim, E.S.Hong, et al. PROPIT: a PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. Clin Endocrinol (Oxf). 2015;82(5):670–677.
36. J.Sasaki, Y.Ikeda, T.Kuribayashi, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089–1101.
37. Y.Cho, E.Choe, Y.H.Lee, et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism. 2015;64(4):482–488.
38. A.J.Vallejo-Vaz, S.R.Kondapally Seshasai, K.Kurogi, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241(2):409–418.•• A meta-analysis showing that pitavastatin does not increase incident diabetes risk.
39. T.Mita, S.Nakayama, H.Abe, et al. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig. 2013;4(3):297–303.
40. P.Y.Liu, L.Y.Lin, H.J.Lin, et al. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLoS One. 2013;8(10):e76298.
41. J.Gumprecht, M.Gosho, D.Budinski, et al. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011;13(11):1047–1055.
42. H.Daido, Y.Horikawa, J.Takeda. The effects of pitavastatin on glucose metabolism in patients with type 2 diabetes with hypercholesterolemia. Diabetes Res Clin Pract. 2014;106(3):531–537.
43. C.K.Chakraborti. Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity. World J Diabetes. 2015;6(15):1296–1308.
44. L.Arnaboldi, A.Corsini. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl. 2015;16:1–27.
45. K.Kurogi, S.Sugiyama, K.Sakamoto, et al. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD studyl. J Cardio. 2013;62(2):87–94.• An interesting study showing the diffential effects of statins on adiponectin levels.
46. S.Nomura, N.Inami, A.Shouzu, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets. 2009;20(1):16–22.
47. Y.Ishihara, K.Ohmori, M.Mizukawa, et al. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis. 2010;212(1):131–138.
48. H.Tsubouchi, T.Inoguchi, T.Sonta, et al. Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med. 2005;39(4):444–452.•• A study showing the reduction of high glucose-induced and diabetes-induced oxidative stress by pitavastatin.
49. T.Fujii, M.Onimaru, Y.Yonemitsu, et al. Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression. Am J Physiol Heart Circ Physiol. 2008;294(6):H2785–H2791.
50. M.Matsumoto, M.Tanimoto, T.Gohda, et al. Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice. Metabolism. 2008;57(5):691–697.
51. H.Mizukami, W.Inaba, K.Takahashi, et al. Augmented reduction of islet β-cell mass in Goto-Kakizaki rats fed high-fat diet and its suppression by pitavastatin treatment. J Diabetes Investig. 2012;3(3):235–244.
52. H.Kakuda, J.Kobayashi, M.Nakato, et al. Short-term effect of pitavastatin treatment on glucose and lipid metabolism and oxidative stress in fasting and postprandial state using a test meal in Japanese men. Cholesterol. 2013;2013:314170.
53. K.Fukuda, T.Matsumura, T.Senokuchi, et al. Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor-γ activation. Biochem Biophys Res Commun. 2015;457(1):23–30.
54. M.-A.Kawashiri, A.Nohara, H.Tada, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther. 2008;83(5):731–739.
55. S.Nomura, A.Shouzu, S.Omoto, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39–45.
56. N.Inami, S.Nomura, A.Shouzu, et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb. 2007;36(1):1–8.
57. M.Banach, C.Serban, S.Ursoniu, et al. Statin therapy and plasma coenzyme Q10 concentrations–a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329–336.
58. J.L.Tarry-Adkins, D.S.Fernandez-Twinn, R.Madsen, et al. Coenzyme Q10 prevents insulin signaling dysregulation and inflammation prior to development of insulin resistance in male offspring of a rat model of poor maternal nutrition and accelerated postnatal growth. Endocrinology. 2015;156(10):3528–3537.
59. T.Yamazaki, J.Kishimoto, C.Ito, et al. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int. 2011;2(3):134–140.
60. M.Odawara, T.Yamazaki, J.Kishimoto et al. Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired glucose tolerance. 2015 [cited 2016 Mar7]. Available from: https://distribute.m-anage.com/from.storage?image=XQl42zTOfqciza%252ffgIH06qRnRg53p84GB58voZSMp1LACl1lcTlEd1XZvJ7Vz6LFJk1ya5R9FT8Qv5MJyMH7%252bQ%253d%253d